Profile of patients treated with omalizumab in routine clinical practice in Spain

被引:10
|
作者
Ancochea, J. [1 ]
Chivato, T. [2 ]
Casan, P. [3 ]
Picado, C. [4 ]
Herraez, L. [5 ]
Casafont, J. [5 ]
机构
[1] Hosp Princesa, Madrid, Spain
[2] Hosp Cent Def, Madrid, Spain
[3] Hosp Univ Cent Asturias, Fac Med, Inst Nacl Silicosis, Oviedo, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain
[5] Novartis Farmaceut SA Barcelona, Dept Med, Barcelona, Spain
关键词
Uncontrolled severe; allergic asthma; Anti-IgE; Omalizumab; Effectiveness; Observational study; ANTI-IGE ANTIBODY; QUALITY-OF-LIFE; ASTHMA INSIGHTS; EXACERBATIONS; VALIDATION; MANAGEMENT; THERAPY; REALITY; VISITS; ADULTS;
D O I
10.1016/j.aller.2012.10.010
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Omalizumab is indicated in patients with severe allergic asthma not controlled by high-dose inhaled glucocorticoids and long-acting beta-agonists. Few data are available on the profile of patients treated with this drug in routine clinical practice in Spain. Objective: To describe the profile of patients with severe allergic asthma treated with omalizumab and the course of the disease after a period of treatment. Methods: Retrospective, multicentre study, recording the data on patients of either sex and >= 12 years with uncontrolled severe allergic asthma, previously treated with omalizumab. Data were evaluated in relation to pulmonary function, symptoms, quality of life, and concomitant anti-asthma treatment before the prescription of omalizumab and at the time of the study visit. Results: 214 patients were evaluable (mean age = 48.2 +/- 17.7 years; mean age at the time of diagnosis = 26.6 +/- 16.5 years). 90.7% had experienced exacerbations the year before receiving omalizumab, and the mean total IgE level was 273 +/- 205.4IU/ml. The mean monthly dose was 380.5 +/- 185.4 mg. Compared with the baseline situation, differences were observed after treatment with omalizumab in mean FEV1 (62.7 +/- 15.9% vs. 70.8 +/- 18.7%), in the proportion of patients requiring oral corticosteroids (47.7% vs. 14.0%), and in the ACQ and AQLQ scores. 32.7% of the patients received doses not recommended by the Summary of Product Characteristics (SPC). Conclusions: Profile of asthmatic patients treated with omalizumab predominantly corresponds to uncontrolled severe asthma cases, in accordance with SPC's indications. The results of the study suggest a favourable clinical course similar to that observed in other studies. (C) 2012 SEICAP. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:102 / 108
页数:7
相关论文
共 50 条
  • [41] Early mortality in patients with cancer treated with immunotherapy in routine practice
    Raphael, J.
    Richard, L.
    Lam, M.
    Blanchette, P.
    Leighl, N.
    Rodrigues, G.
    Trudeau, M. E.
    Krzyzanowska, M. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S895 - S896
  • [42] The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer's disease treated in routine clinical practice in Spain
    Lopez-Pousa, Secundino
    Bermejo-Pareja, Felix
    Frank, Ana
    Hernandez, Francisco
    Leon, Teresa
    Rejas-Gutierrez, Javier
    REVISTA DE NEUROLOGIA, 2010, 51 (10) : 577 - 588
  • [43] Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain
    Jose Ribal, Maria
    Ignacio Martinez-Salamanca, Juan
    Garcia Freire, Camilo
    PROSTATE CANCER, 2015, 2015
  • [44] REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ETANERCEPT (WITH AND WITHOUT METHOTREXATE) IN ROUTINE CLINICAL PRACTICE AS COMPARED TO A CLINICAL TRIAL EXPERIENCE
    Keystone, E. C.
    Cannon, G. W.
    Wang, B. C.
    Park, G. S.
    Koenig, A.
    Collier, D. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 364 - 364
  • [45] Effectiveness and Tolerability of Perampanel in Epilepsy Patients Treated in Routine Clinical Practice: a Global Pooled Analysis Study
    D'Souza, Wendyl
    Trinka, Eugen
    Wu, Tony
    Najm, Imad
    Malhotra, Manoj
    Ngo, Leock Y.
    McMurray, Rob
    Villanueva, Vicente
    NEUROLOGY, 2021, 96 (15)
  • [46] LUMINOUS: baseline characteristics of the first cohort of patients treated with ranibizumab 0.5 mg in routine clinical practice
    Brand, Christopher
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [47] Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France
    Despiegel, Nicolas
    Touboul, Chantal
    Flinois, Alain
    Saba, Grece
    Suzan, Florence
    Gonzalez-McQuire, Sebastian
    Bonnetain, Franck
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01): : E13 - E28
  • [48] Functional recovery in remitted patients treated for major depressive disorder (MDD) in routine clinical practice in Greece
    Chatzimanolis, A.
    Avgerinos, N.
    Dimellis, D.
    Pappas, D.
    Genaris, I.
    Mylonaki, T.
    Papalexi, E.
    EUROPEAN PSYCHIATRY, 2019, 56 : S100 - S101
  • [49] Methods for measuring dose escalation in tnf antagonists for rheumatoid arthritis patients treated in routine clinical practice
    Gu, N. Y.
    Huang, X.
    Globe, D.
    Fox, K. M.
    VALUE IN HEALTH, 2007, 10 (03) : A2 - A2
  • [50] Characterization of Patients With Geographic Atrophy in Routine Clinical Practice
    Conti, Felipe
    Han, Michael M.
    Song, Weilin
    Wai, Karen M.
    Silva, Fabiana Q.
    Singh, Rishi P.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2019, 50 (02): : 93 - 98